Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QURE 
Uniqure NV (QURE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: QURE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $74.79
1 Year Target Price $74.79
| 9 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.41% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.35B USD | Price to earnings Ratio - | 1Y Target Price 74.79 |
Price to earnings Ratio - | 1Y Target Price 74.79 | ||
Volume (30-day avg) 13 | Beta 0.56 | 52 Weeks Range 5.35 - 71.50 | Updated Date 10/29/2025 |
52 Weeks Range 5.35 - 71.50 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When - | Estimate -0.9255 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -790.78% |
Management Effectiveness
Return on Assets (TTM) -15.39% | Return on Equity (TTM) -427.47% |
Valuation
Trailing PE - | Forward PE 27.93 | Enterprise Value 3047128519 | Price to Sales(TTM) 303.31 |
Enterprise Value 3047128519 | Price to Sales(TTM) 303.31 | ||
Enterprise Value to Revenue 212.54 | Enterprise Value to EBITDA 0.99 | Shares Outstanding 61603771 | Shares Floating 37042859 |
Shares Outstanding 61603771 | Shares Floating 37042859 | ||
Percent Insiders 5.41 | Percent Institutions 87.91 |
Upturn AI SWOT
Uniqure NV
Company Overview
History and Background
uniQure N.V. was founded in 1998 in Amsterdam. It is a pioneer in gene therapy, focusing on developing treatments for genetic diseases. Milestones include the approval of Glybera, the first gene therapy product approved in Europe, and the continued development of its gene therapy pipeline.
Core Business Areas
- Gene Therapy for Liver Diseases: Focuses on developing gene therapies targeting liver-expressed proteins to treat diseases like hemophilia B and Huntington's disease.
- Gene Therapy for Central Nervous System (CNS) Diseases: Developing gene therapies to treat neurological disorders by delivering therapeutic genes to the CNS.
- Manufacturing and Technology: Developing and scaling up manufacturing processes for gene therapy products.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives. The company has a functional organizational structure with departments dedicated to research and development, manufacturing, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Etrana Deacogiene (Hemgenix): Etrana Deacogiene (Hemgenix) is indicated for the treatment of adults with severe hemophilia B (congenital factor IX deficiency). This product received regulatory approval in the US. Competitors include other factor IX replacement therapies and potential gene therapies from companies like Pfizer (acquired Spark Therapeutics) and CSL Behring. Peak sales estimated in the $500M - $700M range.
- AMT-130 (Huntington's Disease): AMT-130 is an investigational gene therapy for Huntington's disease. It is currently in clinical trials. Competitors include Wave Life Sciences and Roche/Genentech, both developing antisense oligonucleotides and other therapies targeting Huntington's disease. No revenue as in clinical trials.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, driven by advancements in vector technology and a better understanding of genetic diseases. The industry is characterized by high research and development costs, regulatory hurdles, and potential for high returns on investment.
Positioning
uniQure is a leader in the gene therapy space, with a focus on liver and CNS disorders. Its competitive advantages include its proprietary AAV vector technology and its experience in developing and manufacturing gene therapy products.
Total Addressable Market (TAM)
The total addressable market for gene therapies is estimated to be in the tens of billions of dollars. uniQure is positioned to capture a significant share of this market with its pipeline of gene therapy candidates.
Upturn SWOT Analysis
Strengths
- Pioneering gene therapy company
- Proprietary AAV vector technology
- Experienced management team
- Approved gene therapy product (Hemgenix)
- Strong IP portfolio
Weaknesses
- High research and development costs
- Regulatory hurdles
- Manufacturing complexities
- Reliance on partnerships
- Cash burn
Opportunities
- Expansion into new therapeutic areas
- Partnerships with larger pharmaceutical companies
- Advancements in gene editing technologies
- Increasing regulatory support for gene therapies
- Growing awareness of gene therapies
Threats
- Competition from other gene therapy companies
- Potential safety concerns with gene therapies
- Pricing and reimbursement challenges
- Intellectual property disputes
- Clinical trial failures
Competitors and Market Share
Key Competitors
- PFE
- BLUE
- CRSP
Competitive Landscape
uniQure's advantages include its Hemgenix approval and AAV platform. Disadvantages include its smaller size and reliance on partnerships compared to larger pharmaceutical companies like Pfizer.
Major Acquisitions
No relevant or recent acquisitions made
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by R&D progress and milestone payments.
Future Projections: Future growth is projected to be driven by increased sales of Hemgenix and progress in its pipeline programs. Analyst estimates vary but generally forecast significant revenue growth in the coming years.
Recent Initiatives: Recent strategic initiatives include the commercial launch of Hemgenix and the advancement of AMT-130 into later-stage clinical trials.
Summary
Uniqure is a pioneering gene therapy company with an approved product, Hemgenix, and a promising pipeline. The company faces challenges related to high R&D costs and regulatory hurdles, but significant growth is expected with the continued commercialization of Hemgenix. Future success depends on clinical trial outcomes and market acceptance of its gene therapies. Uniqure's platform technology provides a significant competitive advantage but it must manage resources carefully to avoid running out of cash.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Analyst reports, Press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. The analysis is based on publicly available information and analyst estimates, which are subject to change. Investing in gene therapy companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Uniqure NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-20 | CEO & Executive Director Mr. Matthew Craig Kapusta CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 209 | Website https://www.uniqure.com |
Full time employees 209 | Website https://www.uniqure.com | ||
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.